Author:
Liang Rongxin,Wang Dongxing,Hu Mingjin,Gu Yuxia,Wang Meijun,Hu Dan,Zhu Mingan,Wang Meng
Funder
Shiyan Science and Technology Bureau
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology
Reference40 articles.
1. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74:1315–33.
2. Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics (Basel). 2020;9:205.
3. Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021;48:6987–98.
4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019[M]. US Department of Health and Human Services, Centres for Disease Control and Prevention, 2019.
5. Hu F, Guo Y, Yang Y, Zheng Y, Wu S, Jiang X, et al. China Antimicrobial Surveillance Network (CHINET) Study Group. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38:2275–81.